Ascendis Pharma A/S (NASDAQ:ASND) Position Boosted by Jones Financial Companies Lllp

Jones Financial Companies Lllp grew its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 394.0% in the 4th quarter, HoldingsChannel.com reports. The firm owned 247 shares of the biotechnology company’s stock after purchasing an additional 197 shares during the period. Jones Financial Companies Lllp’s holdings in Ascendis Pharma A/S were worth $34,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Westfield Capital Management Co. LP lifted its position in shares of Ascendis Pharma A/S by 3.4% in the third quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company’s stock worth $766,523,000 after purchasing an additional 170,942 shares in the last quarter. Janus Henderson Group PLC raised its position in Ascendis Pharma A/S by 6.8% during the third quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock valued at $625,075,000 after acquiring an additional 267,881 shares in the last quarter. Massachusetts Financial Services Co. MA raised its position in Ascendis Pharma A/S by 9.1% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock valued at $278,760,000 after acquiring an additional 155,971 shares in the last quarter. Groupama Asset Managment bought a new position in Ascendis Pharma A/S during the third quarter valued at approximately $60,000. Finally, ARS Investment Partners LLC raised its position in Ascendis Pharma A/S by 0.9% during the fourth quarter. ARS Investment Partners LLC now owns 265,480 shares of the biotechnology company’s stock valued at $36,549,000 after acquiring an additional 2,369 shares in the last quarter.

Ascendis Pharma A/S Stock Performance

NASDAQ:ASND opened at $166.05 on Thursday. Ascendis Pharma A/S has a 52-week low of $111.09 and a 52-week high of $169.37. The firm has a market cap of $10.08 billion, a price-to-earnings ratio of -23.39 and a beta of 0.62. The business’s fifty day moving average is $140.06 and its 200 day moving average is $135.30.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.64. Equities analysts predict that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have commented on ASND shares. UBS Group started coverage on Ascendis Pharma A/S in a report on Tuesday, January 7th. They set a “buy” rating and a $196.00 price target on the stock. The Goldman Sachs Group increased their price target on Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a “buy” rating in a report on Thursday, February 13th. StockNews.com upgraded Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Evercore ISI increased their price target on Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an “outperform” rating in a report on Tuesday, February 18th. Finally, JPMorgan Chase & Co. increased their price target on Ascendis Pharma A/S from $168.00 to $200.00 and gave the company an “overweight” rating in a report on Tuesday. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $204.64.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.